CD70 and renal cell carcinoma: In addition, CRISPR Therapeutics has developed another allogeneic CD70 CAR T cells (CTX-130), which has shown early signs of clinical activity in advanced RCC patients, according to findings from the phase 1 COBALT-RCC trial (NCT04438083) [36].